Apremilast for Alcohol Use Disorder
The primary objective of this study is to evaluate the efficacy of two different doses of Apremilast (tablets) versus placebo in reducing alcohol craving among participants with moderate to severe alcohol use disorder (AUD) after two weeks of daily dosing.
Why this Research Matters
This research study should take up to 9 weeks of your time. You will be asked to visit the clinic on the CU Anschutz Campus about 7 times (possibly a few more) and there is a follow-up phone call at the end of the study. During the study, you will have a physical exam and ECG test, give urine and blood samples, do alcohol breathalyzer tests, answer questions and complete questionnaires, and take the study medication or a placebo.
Who can Participate
Inclusion criteria: - Age 21 or older - Drink regularly and meet criteria for Alcohol Use Disorder (AUD) - Seeking treatment to cut down or quit drinking Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.
Study ID
Protocol Number: 25-2638
More information available at ClinicalTrials.gov: NCT07325266
Meet the Team
Principal Investigator